Bolt Biotherapeutics Stock Today
| BOLT Stock | USD 5.66 0.02 0.35% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Bolt Biotherapeutics is selling for under 5.66 as of the 19th of June 2025; that is 0.35 percent up since the beginning of the trading day. The stock's last reported lowest price was 5.64. Bolt Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of March 2025 and ending today, the 19th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. The company has 1.92 M outstanding shares of which 430.33 K shares are currently shorted by private and institutional investors with about 0.64 trading days to cover. More on Bolt Biotherapeutics
Moving together with Bolt Stock
Moving against Bolt Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bolt Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Jakarta Stock Exchange, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBolt Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bolt Biotherapeutics' financial leverage. It provides some insight into what part of Bolt Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bolt Biotherapeutics (BOLT) is traded on NASDAQ Exchange in USA. It is located in 900 Chesapeake Drive, Redwood City, CA, United States, 94063 and employs 52 people. Bolt Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.85 M. Bolt Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.92 M outstanding shares of which 430.33 K shares are currently shorted by private and institutional investors with about 0.64 trading days to cover.
Bolt Biotherapeutics currently holds about 176.34 M in cash with (61.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68.
Check Bolt Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Bolt Biotherapeutics is $10.85 Million. 30% of Bolt Biotherapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Bolt Ownership Details
Bolt Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adar1 Capital Management Llc | 2025-03-31 | 245 K | |
| Squarepoint Ops Llc | 2025-03-31 | 83.9 K | |
| Ubs Group Ag | 2024-12-31 | 66.1 K | |
| State Street Corp | 2025-03-31 | 47.4 K | |
| Northern Trust Corp | 2025-03-31 | 40.9 K | |
| Mariner Wealth Advisors Llc | 2024-12-31 | 35 K | |
| Susquehanna International Group, Llp | 2025-03-31 | 21.7 K | |
| Stonex Group Inc | 2025-03-31 | 15.5 K | |
| Xtx Topco Ltd | 2025-03-31 | 15.4 K | |
| Tang Capital Management Llc | 2025-03-31 | 3.8 M | |
| Vivo Capital, Llc | 2025-03-31 | 3.5 M |
Bolt Biotherapeutics Historical Income Statement
Bolt Stock Against Markets
Bolt Biotherapeutics Corporate Management
| Randall Schatzman | CEO Director | Profile | |
| Justin Kenkel | Senior Scientist | Profile | |
| Edith MD | Chief Officer | Profile | |
| Michael Alonso | Senior Research | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ming Yin | VP Biometrics | Profile |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.